A novel evaluation of optimality for randomized controlled trials
Jo Wick(University of Kansas Medical Center), Byron J. Gajewski(University of Kansas Medical Center), Scott Berry(Queen's University), Christina M. Pacheco(University of Kansas Medical Center), Christine Makosky Daley(American Indian Center), Won S. Choi(University of Kansas Medical Center), Hung‐Wen Yeh(Tulsa Community College)
Cited by 8
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818